D.A. Davidson & CO. Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

D.A. Davidson & CO. increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 16.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,937 shares of the company’s stock after purchasing an additional 5,565 shares during the period. D.A. Davidson & CO.’s holdings in Moderna were worth $2,669,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the second quarter worth about $26,000. Family Firm Inc. purchased a new position in Moderna in the 2nd quarter worth approximately $33,000. Bank & Trust Co acquired a new stake in Moderna in the second quarter valued at approximately $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna during the second quarter valued at approximately $48,000. Finally, Plato Investment Management Ltd lifted its position in shares of Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Leerink Partners lowered their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Wolfe Research started coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their price target for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Jefferies Financial Group lowered their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Finally, Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $83.33.

Moderna Stock Down 0.8 %

NASDAQ:MRNA opened at $43.06 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $52.38 and a 200-day moving average of $91.36. The firm has a market capitalization of $16.57 billion, a PE ratio of -7.40 and a beta of 1.69. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. Analysts predict that Moderna, Inc. will post -9.44 EPS for the current year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 1,147 shares of company stock worth $76,245 in the last ninety days. 15.70% of the stock is owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.